Drugmakers Saw Robust ROI and Lower Development Costs in 2021, Says Analysis Post author:PacConAdmin Post published:January 12, 2022 Post category:Drug Industry Daily It’s been a banner year for the financial side of the pharmaceutical industry. Source: Drug Industry Daily You Might Also Like J&J Files Arbitration Demand in Emergent Dispute August 2, 2022 Bayer Racks Kerendia Win in Subgroup Analysis August 29, 2022 Ranier’s Compounding Laboratory Draws Form 483, Safety Alert Over Sterility Issues July 11, 2018